The results indicated that a high expression of MICB mRNA was significantly associated with poor PFS in ovarian cancer patients, including ovarian serous carcinoma and ovarian endometrioid adenocarcinoma patients (Figure 8). This evidence concerns the gene MICB and ovarian carcinoma.